ArticleGastroenterology and hepatology from bed to bench2025
Gut microbiome dysbiosis and inflammatory markers in severe COVID-19: links to atherosclerosis and potential therapeutic insights.
Article in Gastroenterology and hepatology from bed to bench, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COVID-19 is implicated in the exacerbation of atherosclerosis, potentially leading to its clinical manifestations. The aim of this study was to evaluate serum biomarkers, including albumin (ALB), C-reactive protein (CRP), ferritin (FERR), CD16, CD18, NLRP3, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), in patients with COVID-19. In addition, assessment of microbiome profiles may provide insights into disease severity and gastrointestinal health. Method: In this case-control study, serum samples were collected from 90 individuals: 30 patients with COVID-19 admitted to the intensive care unit, 30 hospitalized patients with COVID-19, and 30 healthy individuals. Concentrations of ALB, CRP, FERR, NLRP3, CD16, CD18, IL-6, and TNF-α were measured. Quantitative PCR (qPCR) was used to assess microbial diversity in stool samples. Result: No significant age difference was noted between the patient (55.40 ± 10.34 years) and the control groups (58.34 ± 11.71 years). Substantial increases in CRP, CD-18, CD-16, IL-6, Alb, and TNF-α (P < 0.001) were observed in severe cases compared to non-severe cases. Microbiome analysis indicated a 40% decrease in Roseburia and a 35% reduction in Faecalibacterium in ICU patients. Conclusion: Evaluating these biomarkers provides critical insights into atherosclerosis susceptibility in COVID-19 patients and reveals meaningful relationships among COVID-19, atherosclerosis, and gastrointestinal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.